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background:  Few data exist on bivalirudin’s clinical safety and efficacy in the context of contemporary antiplatelet treatment.
methods: We monitored in-hospital and 30-day bleeding events (Bleeding Academic Research Consortium -BARC classification) and major adverse 
cardiovascular events (MACEs) in the context of a prospective multi-centre, observational study in patients with acute coronary syndrome (ACS) 
subjected to percutaneous coronary intervention (PCI) in Greece.
results: Out of 2047 patients registered, 480(23.4%) were treated with bivalirudin and 1708 were used for outcomes assessment (Figure). In 
multivariate analysis (C-statistic 0.76, 0.74-0.79 95%CIs, p=0.01) primary PCI, prior bleeding and use of novel P2Y12 inhibitor favored bivalirudin 
use whereas IIb/IIIa inhibitor use did not [OR(95%CI) = 3.34(2.6-4.3), 1.42(1.008-2), 1.54(1.2-1.9) and 0.32(0.2-0.5) respectively, all p<0.001]. 
Regional trends also affected choice of bivalirudin. Among 371 propensity matched pairs of patients MACEs, BARC1, BARC2 and BARC3 bleeding 
events did not differ significantly between bivalirudin and no bivalirudin-treated individuals (3.8% vs 4.3%, 20.2% vs 19.9%, 3.8% vs 2.4% and 3.5% 
vs 3.5%, all p>0.1).
Conclusions: In a real-world ACS population subjected to PCI and receiving contemporary antiplatelet therapy, bivalirudin use was not associated 
with lower risk of bleeding events.
 
